Health
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants – PharmiWeb.com
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase…
- The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
- Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or…
Continue Reading
-
Noosa News19 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News22 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
Noosa News19 hours agoHomicide investigation underway after woman found dead in north Brisbane
-
Noosa News12 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane